Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.

Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):53-63. doi: 10.1016/j.clml.2018.08.020. Epub 2018 Sep 10.

PMID:
30301673
2.

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.

Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT.

Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18.

3.

Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation.

Tomac G, Bojanić I, Mazić S, Vidović I, Raos M, Ćepulić BG, Seiwerth RS, Kelečić J, Labar B.

Blood Transfus. 2018 Jul;16(4):397-404. doi: 10.2450/2017.0322-16. Epub 2017 Apr 19.

4.

The effect of HLA allele and haplotype polymorphisms on donor matching in hematopoietic stem cell transplantation - Croatian experience.

Grubic Z, Stingl Jankovic K, Maskalan M, Serventi-Seiwerth R, Mikulic M, Nemet D, Burek Kamenaric M, Labar B, Zunec R.

Hum Immunol. 2016 Dec;77(12):1120-1127. doi: 10.1016/j.humimm.2016.10.004. Epub 2016 Oct 15.

PMID:
27756586
5.

High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.

Aurer I, Nemet D, Mitrović Z, Dujmović D, Bašić-Kinda S, Radman I, Sertić D, Šantek F, Kralik M, Dotlić S, Mazić S, Labar B.

Ann Hematol. 2016 Jun;95(7):1129-36. doi: 10.1007/s00277-016-2676-0. Epub 2016 Apr 22.

PMID:
27103009
6.

Venous thromboembolism in Croatia - Croatian Cooperative Group for Hematologic Diseases (CROHEM) study.

Pulanić D, Gverić-Krečak V, Nemet-Lojan Z, Holik H, Coha B, Babok-Flegarić R, Komljenović M, Knežević D, Petrovečki M, Zupančić Šalek S, Labar B, Nemet D.

Croat Med J. 2015 Dec;56(6):550-7.

7.

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.

Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.

Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.

8.

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).

Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.

Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.

9.

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.

Batinić J, Perić Z, Šegulja D, Last J, Prijić S, Dubravčić K, Volarić L, Sertić D, Radman I, Bašić-Kinda S, Matišić D, Batinić D, Labar B, Nemet D.

Croat Med J. 2015 Jun;56(3):263-71.

10.

Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.

Prijić S, Ugrina I, Labar B, Nemet D, Batinić J, Zadro R, Ries S, Gjadrov-Kuvedžić K, Davidović S, Batinić D.

Leuk Lymphoma. 2015;56(8):2281-8. doi: 10.3109/10428194.2014.990012. Epub 2014 Dec 29.

PMID:
25426669
11.

High numbers of mobilized CD34+ cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT.

Hengeveld M, Suciu S, Chelgoum Y, Marie JP, Muus P, Lefrère F, Mandelli F, Pane F, Amadori S, Fioritoni G, Labar B, Baron F, Cermak J, Bourhis JH, Storti G, Fazi P, Hagemeijer A, Vignetti M, Willemze R, de Witte T.

Bone Marrow Transplant. 2015 Mar;50(3):341-7. doi: 10.1038/bmt.2014.262. Epub 2014 Nov 17.

12.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
13.

Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.

Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH.

Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29.

PMID:
24994606
14.

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T.

J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2.

15.

Therapy-related acute myeloblastic leukemia after splenectomy in a patient with composite lymphoma developing after treatment of chronic lymphocytic leukemia.

Valković T, Seili-Bekafigo I, Bašić-Kinda S, Labar B, Duletić-Načinović A, Pećanić S, Jonjić N.

Ann Hematol. 2014 Jun;93(6):1057-9. doi: 10.1007/s00277-013-1917-8. Epub 2013 Oct 8. No abstract available.

PMID:
24101115
16.

[Extracorporeal photopheresis in treatment of chronic graft versus host disease].

Bojanić I, Seiwerth RS, Mazić S, Dubravcić K, Batinić D, Cepulić BG, Labar B.

Lijec Vjesn. 2013 May-Jun;135(5-6):139-44. Croatian.

PMID:
23898694
17.

Treatment of chronic GVHD with extracorporeal photochemotherapy.

Bojanic I, Serventi Seiwerth R, Golubic Cepulic B, Mazic S, Lukic M, Raos M, Plenkovic F, Golemovic M, Dubravcic K, Perkovic S, Batinic D, Labar B.

Transfus Apher Sci. 2013 Apr;48(2):193-4. doi: 10.1016/j.transci.2013.02.033. Epub 2013 Mar 17. No abstract available.

PMID:
23809831
18.

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.

Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M, Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lübbert M.

Haematologica. 2013 Feb;98(2):208-16. doi: 10.3324/haematol.2012.067892. Epub 2012 Aug 8.

19.

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.

Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G.

Eur J Clin Invest. 2012 Sep;42(9):1016-26. doi: 10.1111/j.1365-2362.2012.02675.x. Epub 2012 May 1. Review.

PMID:
22548456
20.
21.

[Diagnostic approach and therapy for cytomegalovirus (CMV) infection following allogeneic stem cell transplantation].

Beader N, Kalenić S, Labar B.

Lijec Vjesn. 2011 Nov-Dec;133(11-12):389-96. Review. Croatian.

PMID:
22329295
22.

Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia.

Dujmovic D, Aurer I, Radman I, Serventi-Seiwerth R, Dotlic S, Stern-Padovan R, Dubravcic K, Santek F, Labar B.

Acta Haematol. 2012;127(2):115-7. doi: 10.1159/000334705. Epub 2011 Dec 31. No abstract available.

PMID:
22212303
23.

Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.

Basak GW, Jaksic O, Koristek Z, Mikala G, Mayer J, Masszi T, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukemia Group (CELG).

Am J Hematol. 2011 Jul;86(7):550-3. doi: 10.1002/ajh.22038. Epub 2011 Jun 14.

24.

Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.

Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A, Reti M, Masszi T, Mayer J, Giebel S, Hübel K, Labar B, Wiktor-Jedrzejczak W.

Leuk Lymphoma. 2011 Sep;52(9):1711-9. doi: 10.3109/10428194.2011.578312. Epub 2011 Jun 12.

PMID:
21663509
25.

Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.

Durakovic N, Radojcic V, Boban A, Mrsic M, Sertic D, Serventi-Seiwerth R, Nemet D, Labar B.

Intern Med. 2011;50(9):1009-13. Epub 2011 May 1.

26.

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.

Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW.

J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11.

PMID:
21483003
27.

Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.

Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J, Masszi T, Giebel S, Labar B, Wiktor-Jedrzejczak W; Central and Eastern European Leukaemia Group (CELG).

Eur J Haematol. 2011 Jun;86(6):488-95. doi: 10.1111/j.1600-0609.2011.01605.x. Epub 2011 Apr 1.

PMID:
21410533
28.

Large volume leukapheresis: Efficacy and safety of processing patient's total blood volume six times.

Bojanic I, Dubravcic K, Batinic D, Cepulic BG, Mazic S, Hren D, Nemet D, Labar B.

Transfus Apher Sci. 2011 Apr;44(2):139-47. doi: 10.1016/j.transci.2011.01.005. Epub 2011 Feb 12.

PMID:
21320801
29.

[Diagnosis and therapy for patients with essential thrombocythemia. Guidelines of Croatian Cooperative Group for hematologic disorders--KROHEM].

Labar B, Kusec R, Jaksić B, Skare-Librenjak L, Nacinović-Duletić A, Petricević-Sincić J, Carzavec D, Coha B, Gverić-Krecak V, Corović E, Lang N, Lojen-Nemet Z, Babok-Flegarić R; Croatian Cooperative Group for hematologic disorders.

Lijec Vjesn. 2010 Nov-Dec;132(11-12):333-9. Croatian.

PMID:
21294321
30.

The European LeukemiaNet: achievements and perspectives.

Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach C, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S; European LeukemiaNet.

Haematologica. 2011 Jan;96(1):156-62. doi: 10.3324/haematol.2010.032979. Epub 2010 Nov 3.

31.

Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.

Mitrović Z, Ilić I, Aurer I, Kinda SB, Radman I, Dotlić S, Ajduković R, Labar B.

Pathol Oncol Res. 2011 Jun;17(2):243-7. doi: 10.1007/s12253-010-9304-4. Epub 2010 Sep 18.

PMID:
20853074
32.

Apoptosis of leukemic cells: a case report.

Vrbanus L, Sucić M, Marković-Glamocak M, Ries S, Gjadrov-Kuvezdić K, Fabijanić I, Antulov J, Petrik J, Labar B.

Coll Antropol. 2010 Jun;34(2):705-11.

PMID:
20698159
33.

Collection and composition of autologous peripheral blood stem cells graft in patients with acute myeloid leukemia: influence on hematopoietic recovery and outcome.

Raos M, Nemet D, Bojanić I, Sertić D, Batinić D, Dusak V, Dubravcić K, Mazić S, Serventi-Seiwerth R, Mrsić M, Golubić-Cepulić B, Labar B.

Coll Antropol. 2010 Mar;34(1):105-15.

PMID:
20437639
34.

FNA based diagnosis of head and neck nodal lymphoma.

Kuvezdić KG, Aurer I, Ries S, Sucić M, Glamocak MM, Ilić I, Basić-Kinda S, Radman I, Labar B.

Coll Antropol. 2010 Mar;34(1):7-12.

PMID:
20437634
35.

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.

Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N.

Haematologica. 2010 Sep;95(9):1548-54. doi: 10.3324/haematol.2009.020586. Epub 2010 Apr 23.

36.

Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.

Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T; EORTC Leukemia Group.

Haematologica. 2010 Sep;95(9):1489-95. doi: 10.3324/haematol.2009.018580. Epub 2010 Apr 7.

37.

[World's registry of bone marrow donors].

Cecuk-Jelicić E, Kerhin-Brkljacić V, Grubic Z, Labar B.

Acta Med Croatica. 2009 Jun;63(3):251-3. Croatian.

PMID:
19827354
38.

[Plasticity of hematopoietic stem cells].

Labar B.

Acta Med Croatica. 2009 Jun;63(3):227-30. Review. Croatian.

PMID:
19827350
39.

[Twenty years of severe aplastic anemia treatment at Department of Hematology, University Department of Medicine, Zagreb University Hospital Center, Zagreb, Croatia].

Mrsić M, Seiwerth RS, Labar B, Bogdanić V, Nemet D, Duraković N, Mikulić M, Sertić D, Aurer I, Radman I, Zupancić-Salek S.

Acta Med Croatica. 2009 Jun;63(3):209-14. Croatian.

PMID:
19827347
40.

[Treatment of acute leukemia with allogeneic stem cell transplantation].

Seiwerth RS, Mrsić M, Nemet D, Bogdanić V, Mikulić M, Sertić D, Grković L, Cecuk E, Bojanić I, Batinić D, Labar B.

Acta Med Croatica. 2009 Jun;63(3):205-8. Croatian.

PMID:
19827346
41.

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di Raimondo F, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T.

J Clin Oncol. 2009 Nov 10;27(32):5397-403. doi: 10.1200/JCO.2008.20.6490. Epub 2009 Oct 13. Erratum in: J Clin Oncol. 2010 Mar 10;28(8):1438.

42.

[Thrombophilia--inherited and acquired susceptibility to thrombosis].

Pulanić D, Salek SZ, Labar B.

Lijec Vjesn. 2009 Jul-Aug;131(7-8):236-7. Croatian. No abstract available.

PMID:
19769289
43.

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab.

Ilić I, Mitrović Z, Aurer I, Bašić-Kinda S, Radman I, Ajduković R, Labar B, Dotlić S, Nola M.

Int J Hematol. 2009 Jul;90(1):74-80. doi: 10.1007/s12185-009-0353-y. Epub 2009 Jun 3.

PMID:
19495929
44.

CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.

Mitrovic Z, Ilic I, Nola M, Aurer I, Sonicki Z, Basic-Kinda S, Radman I, Ajdukovic R, Labar B.

Clin Lymphoma Myeloma. 2009 Apr;9(2):133-7. doi: 10.3816/CLM.2009.n.033.

PMID:
19406723
45.

Treatment of multiple relapsing non-melanoma skin cancers in a patient with severe hemophilia A.

Salek SZ, Radman I, Pulanic D, Pasic A, Nola M, Labar B.

Tumori. 2009 Jan-Feb;95(1):115-8.

PMID:
19366070
46.

Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.

Giebel S, Labopin M, Holowiecki J, Labar B, Komarnicki M, Koza V, Masszi T, Mistrik M, Lange A, Hellmann A, Vitek A, Pretnar J, Mayer J, Rzepecki P, Indrak K, Wiktor-Jedrzejczak W, Wojnar J, Krawczyk-Kulis M, Kyrcz-Krzemien S, Rocha V.

Ann Hematol. 2009 Oct;88(10):1005-13. doi: 10.1007/s00277-009-0719-5. Epub 2009 Mar 20.

PMID:
19301005
47.

[Biphenotypic and bilineal acute leukemias].

Batinić D, Dubravcić K, Rajić L, Mikulić M, Labar B.

Acta Med Croatica. 2008 Oct;62(4):387-90. Review. Croatian.

PMID:
19209464
48.

[Current approach to diagnosis and treatment of acute leukemia in adults].

Labar B, Nemet D, Sucić M, Batinić D, Zadro R, Mrsić S, Serventi-Seiwerth R, Sertić D, Mikulić M, Duraković N.

Acta Med Croatica. 2008 Oct;62(4):403-8. Croatian.

PMID:
19205417
49.

[Cytomorphology of acute mixed leukemia].

Sucić M, Batinić D, Zadro R, Mrsić S, Labar B.

Acta Med Croatica. 2008 Oct;62(4):379-85. Croatian.

PMID:
19205415
50.

Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.

Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B.

J Chemother. 2008 Oct;20(5):640-4.

PMID:
19048695

Supplemental Content

Support Center